VEGFR-1 expression levels predict occurrence of disseminated tumor cells in the bone marrow of patients with esophageal carcinoma

Clinical and Experimental Metastasis

Volumn 29, Issue 8, 2012, Pages 879-887

  Schultze, Alexander ^a   Ben Batalla, Isabel ^a   Riethdorf, Sabine ^a   Bubenheim, Michael ^b   Yekebas, Emre ^a,f   Erbersdobler, Andreas ^c   Reichelt, Uta ^d   Effenberger, Katharina E ^a   Schmidt, Thomas ^e   Izbicki, Jakob R ^a   Bokemeyer, Carsten ^a   Pantel, Klaus ^a   Fiedler, Walter ^a   Loges, Sonja ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b HÔPITAL CHARLES NICOLLE   (France)

^c UNIVERSITY OF ROSTOCK   (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e UNIVERSITY OF HEIDELBERG   (Germany)

^f Hospital of Darmstadt   (Germany)

Author keywords

DTCs; Esophageal cancer; Micrometastases; PLGF; VEGFR 1

Indexed keywords

MESSENGER RNA; PLACENTAL GROWTH FACTOR; PLACENTAL GROWTH FACTOR 1; PLACENTAL GROWTH FACTOR 2; PLACENTAL GROWTH FACTOR 3; PLACENTAL GROWTH FACTOR 4; UNCLASSIFIED DRUG; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 1; ISOPROTEIN; MONOCLONAL ANTIBODY; PLACENTA PROTEIN;

ADULT; AGED; ARTICLE; BONE MARROW METASTASIS; CANCER SURVIVAL; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE SEVERITY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS CARCINOMA; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METASTASIS; MICROMETASTASIS; PREDICTION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL TIME; TUMOR CELL; BONE MARROW; BONE MARROW CANCER; ESOPHAGUS TUMOR; GENETICS; IMMUNOLOGY; METABOLISM; MIDDLE AGED; MOLECULAR GENETICS; NEOVASCULARIZATION (PATHOLOGY); NUCLEOTIDE SEQUENCE;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; BASE SEQUENCE; BONE MARROW; BONE MARROW NEOPLASMS; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; NEOVASCULARIZATION, PATHOLOGIC; PREGNANCY PROTEINS; PROTEIN ISOFORMS; RNA, MESSENGER; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 84872864220     PISSN: 02620898     EISSN: 15737276     Source Type: Journal    
DOI: 10.1007/s10585-012-9477-1     Document Type: Article

References (37)

1. Kerbel RS (2008) Tumor angiogenesis. N Engl J Med 358:2039-2049
2. Ellis LM, Hicklin DJ (2008) VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev 8:579-591
3. Bergers G, Hanahan D (2008) Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8:592-603
4. Fischer C, Mazzone M, Jonckx B et al (2008) FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy? Nat Rev 8:942-956
5. Autiero M, Waltenberger J, Communi D et al (2003) Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat Med 9:936-943
6. Luttun A, Tjwa M, Moons L et al (2002) Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med 8:831-840
7. Casanovas O, Hicklin DJ, Bergers G et al (2005) Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8:299-309
8. Motzer RJ, Michaelson MD, Redman BG et al (2006) Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24:16-24
9. Fischer C, Jonckx B, Mazzone M et al (2007) Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 131:463-475
10. Chen CN, Hsieh FJ, Cheng YM et al (2004) The significance of placenta growth factor in angiogenesis and clinical outcome of human gastric cancer. Cancer Lett 213:73-82
11. Parr C, Watkins G, Boulton M et al (2005) Placenta growth factor is over-expressed and has prognostic value in human breast cancer. Eur J Cancer 41:2819-2827
12. Wei SC, Tsao PN, Yu SC et al (2005) Placenta growth factor expression is correlated with survival of patients with colorectal cancer. Gut 54:666-672
13. Zhang L, Chen J, Ke Y et al (2005) Expression of Placenta growth factor (PlGF) in non-small cell lung cancer (NSCLC) and the clinical and prognostic significance. World J Surg Oncol 3:68
14. Escudero-Esparza A, Martin TA, Davies ML et al (2009) PGF isoforms, PLGF-1 and PGF-2, in colorectal cancer and the prognostic significance. Cancer Genomics Proteomics 6:239-246
15. Escudero-Esparza A, Martin TA, Douglas-Jones A et al (2010) PGF isoforms, PLGF-1 and PGF-2 and the PGF receptor, neuropilin, in human breast cancer: prognostic significance. Oncol Rep 23:537-544
16. Loges S, Schmidt T, Carmeliet P (2009) "Antimyeloangiogenic" therapy for cancer by inhibiting PlGF. Clin Cancer Res 15:3648-3653
17. Mazzone M, Dettori D, Leite de Oliveira R et al (2009) Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. Cell 136:839-851
18. Rozen S, Skaletsky H (2000) Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol 132:365-386
19. Loges S, Clausen H, Reichelt U et al (2007) Determination of microvessel density by quantitative real-time PCR in esophageal cancer: correlation with histologic methods, angiogenic growth factor expression, and lymph node metastasis. Clin Cancer Res 13:76-80
20. Bustin SA, Benes V, Garson JA et al (2009) The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem 55:611-622
21. Gath HJ, Heissler E, Hell B et al (1995) Immunocytologic detection of isolated tumor cells in bone marrow of patients with squamous cell carcinomas of the head and neck region. Int J Oral Maxillofac Surg 24:351-355
22. Kaifi JT, Yekebas EF, Schurr P et al (2005) Tumor-cell homing to lymph nodes and bone marrow and CXCR4 expression in esophageal cancer. J Natl Cancer Inst 97:1840-1847
23. Sowter HM, Corps AN, Evans AL et al (1997) Expression and localization of the vascular endothelial growth factor family in ovarian epithelial tumors. Laboratory investigation. J Tech Methods Pathol 77:607-614
24. Xu L, Jain RK (2007) Down-regulation of placenta growth factor by promoter hypermethylation in human lung and colon carcinoma. Mol Cancer Res 5:873-880
25. Amaoka N, Saio M, Nonaka K et al (2006) Expression of vascular endothelial growth factor receptors is closely related to the histological grade of hepatocellular carcinoma. Oncol Rep 16:3-10
26. Andre T, Kotelevets L, Vaillant JC et al (2000) Vegf, Vegf-B, Vegf-C and their receptors KDR, FLT-1 and FLT-4 during the neoplastic progression of human colonic mucosa. Int J Cancer 86:174-181
27. Donnem T, Al-Saad S, Al-Shibli K et al (2007) Inverse prognostic impact of angiogenic marker expression in tumor cells versus stromal cells in non small cell lung cancer. Clin Cancer Res 13:6649-6657
28. Fragoso R, Igreja C, Clode N et al (2008) VEGF signaling on hematopoietic precursors restricts B-lymphoid commitment in vitro and in vivo. Exp Hematol 36(10):1329-1336
29. Ghanem MA, van Steenbrugge GJ, Sudaryo MK et al (2003) Expression and prognostic relevance of vascular endothelial growth factor (VEGF) and its receptor (FLT-1) in nephroblastoma. J Clin Pathol 56:107-113
30. Hahn D, Simak R, Steiner GE et al (2000) Expression of the VEGF-receptor Flt-1 in benign, premalignant and malignant prostate tissues. The Journal of urology 164:506-510
31. Plate KH, Breier G, Millauer B et al (1993) Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis. Cancer Res 53:5822-5827
32. Schmidt M, Voelker HU, Kapp M et al (2008) Expression of VEGFR-1 (Flt-1) in breast cancer is associated with VEGF expression and with node-negative tumour stage. Anticancer Res 28:1719-1724
33. Takanami I, Tanaka F, Hashizume T et al (1997) Vascular endothelial growth factor and its receptor correlate with angiogenesis and survival in pulmonary adenocarcinoma. Anticancer Res 17:2811-2814
34. Kato H, Yoshikawa M, Miyazaki T et al (2002) Expression of vascular endothelial growth factor (VEGF) and its receptors (Flt-1 and Flk-1) in esophageal squamous cell carcinoma. Anticancer Res 22:3977-3984
35. Rades D, Golke H, Schild SE et al (2008) Impact of VEGF and VEGF receptor 1 (FLT1) expression on the prognosis of stage III esophageal cancer patients after radiochemotherapy. Strahlenther Onkol 184:416-420
36. Gockel I, Moehler M, Frerichs K et al (2008) Co-expression of receptor tyrosine kinases in esophageal adenocarcinoma and squamous cell cancer. Oncol Rep 20:845-850
37. Pantel K, Brakenhoff RH, Brandt B (2008) Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat Rev 8:329-340